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INTRODUCTION
Hepatocellular carcinoma (HCC) is the third most 
common cause of  cancer death in the world. It results in 
598 000 deaths per year worldwide. Because of  its poor 
prognosis, this number of  deaths is almost the same as the 
number of  cases being diagnosed each year (626 000)[1]. 
From a global perspective, the two most important risk 
factors for HCC are chronic hepatitis B and C infection. 
The geographic distribution patterns of  HCC and hepatits 
B virus (HBV) almost coincide with each other. The 
characteristics of  patients with HCC are influenced by 
the etiology and the status of  the underlying liver disease. 
The understanding of  its natural history may influence the 
prognosis and choice of  treatment.
HISTORY OF HCC
HCC was believed to be a rare disease in the early 1900s. 
In Germany, Eggel found only 163 cases of  HCC 
autopsies when he surveyed the world literature for HCC. 
He proposed an anatomical classification that HCC was 
classified as nodular, massive and diffuse[2]. However, it 
was found that the disease was more prevalent outside 
Europe. In 1911, Yamagiwa suggested a classification 
based on the origin of  the cancer cell, hepatocellular and 
cholangiocellular, with the terminology of  “hepatoma” 
and “cholangioma” respectively. After Berman’s report 
of  the extremely high HCC incidence among young 
Mozambican males in 1951, the interest in the studies 
of  HCC increased. It has been shown that there is great 
regional difference in the pathology and epidemiology of  
the condition.  
DIFFERENT HCC PATTERNS
HCCs in South Africa are mostly large sized and poorly 
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Abstract
Hepatocellular carcinoma (HCC) is an important cause 
of cancer death in the world. It has great regional 
differences in the pathology and epidemiology. The 
variation is greatly influenced by the aetiologies of 
the disease. Hepatitis B and C infection are the most 
important risk factors. HCC incidence rates are higher 
but in decreasing trend in developing countries. 
However, the figures in the developed countries are 
contrary. Successful hepatitis B virus (HBV) vaccination 
programs, better food hygiene, increased global hepatitis 
C virus (HCV) prevalence and population migration are 
the possible explanations. A number of clinical and 
pathogenic differences exist between HBV- and HCV-
related HCC. HBV infection leads to the development 
of HCC through direct and indirect pathways as it has 
the ability to integrate into the host genome affecting 
cellular signaling and growth control. HCV causes HCC 
mainly through indirect pathways: chronic inflammation, 
cell deaths and proliferation. As a result, HCC is almost 
exclusively found in cirrhotic HCV patients while HCC is 
sometimes found in HBV patients without significant liver 
cirrhosis. Due to the different severities of liver cirrhosis 
and HCC extent, therapeutic strategies from resection, 
liver transplantation to symptoms palliation are available. 
Poorly differentiated histology, lack of fibrous capsule, 
large tumour size, early vascular invasion and elevated 
serum levels of alpha fetoprotein (AFP) are the features 
for more aggressive disease. Combined with markers of 
liver reserve and performance status, accurate scoring 
systems and models have been developed to predict 
patients’ survival and match best treatment option. 
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differentiated with relatively healthy surrounding liver 
tissues. On the contrary, HCCs in non-African countries 
are relatively smaller in size and more differentiated with 
a background of  cirrhotic liver. This can be the result of  
the difference in aetiologies. Aflatoxin B1, a mycotoxin 
produced by Aspergillus species, is believed to be a major 
carcinogenic factor in the South African population. 
Chronic hepatitis and the resultant cirrhosis are believed 
to be important risk factors in non-Africans. The distinct 
fibrolamellar type of  HCC almost exclusively found in 
young Caucasian patients may be due to ethnic factor.
HCC INCIDENCE
Liver cancer incidence rate varies widely from 52.1 per 
100 000 in China to 5.1 per 100 000 in Northern Europe. 
Developing countries contribute more than 80% of  cases 
with China alone accounting for 55%[1]. Other areas 
with high incidences are sub-Saharan Africa, eastern and 
southeastern Asia, and Melanesia. In the past decades, 
liver cancer incidence has decreased in some areas with 
high incidence in the past such as Shanghai, Singapore 
and Hong Kong. However, the opposite was reported 
in some of  the countries in Europe, North America and 
Oceania. It is believed that effective HBV vaccination 
programmes and the better control of  aflatoxin exposure 
in the high HCC incidence areas are contributing to the 
decreased HCC incidence while the increasing HCC 
incidence in some of  the western countries is attributed 
to the increasing prevalence of  hepatitis C virus (HCV) 
infection and immigration of  people from countries with 
high endemicity for HBV infection.
RISK FACTORS FOR HCC
The main established risk factors for HCC development 
are chronic vira l hepat i t is B and C infect ion and 
aflatoxin B1. Liver cirrhosis per se may also lead to HCC 
development. Hepatits C infection probably causes HCC 
through the pathway of  cirrhosis. Alcoholic liver disease, 
autoimmune liver diseases, primary hemochromatosis and 
Wilson’s disease are also associated with the development 
of  HCC. Overall, hepatitis B and C infections are causally 
associated with over 80% of  HCC in the world[3]. 
Worldwide, there are 400 million people infected 
with chronic hepatitis B, seventy five percent of  whom 
are Asians. The natural history of  chronic hepatitis B 
infection in Asian and African countries is different 
from that in the western world. In Asia and Africa, the 
majority of  the people acquire the infection during the 
perinatal period or during very early childhood. There is 
a characteristically prolonged immune tolerance phase 
in the first few decades of  life. The HBV viral loads 
are high and the liver transaminases are nearly normal. 
The lifetime risk of  HCC in infected men is estimated 
to be 10% to 25% while the risk in women is somewhat 
lower[3]. Case-control studies have shown that chronic 
HBV carriers have more than 100-fold increased risk 
of  HCC compared with non-infected individuals.  
Furthermore, the risk of  HCC development is related to 
the disease status of  chronic hepatitis B infection. For 
example, the estimated annual risk of  HCC in chronic 
carriers is 0.26% to 0.6%. The risk increases to 1% in 
patients with active hepatitis[4]. It further increases to 
2% to 3% in cirrhotic patients. Certain viral status also 
poses a higher risk of  HCC. Studies in Taiwan showed 
that genotype C chronic hepatitis B infection has a more 
aggressive progression than genotype B in HBeAg-
positive patients[5]. Core promoter mutations (T1762/
A1764) are also found to be related to a more progressive 
disease[6]. In the majority of  HCC cases (70% to 90%) 
there is underlying liver cirrhosis. However, HBV, being 
an oncogenic virus, can cause HCC in the absence of  
cirrhosis through the pathway of  integration into the 
human genome. 
HBV CARCINOGENESIS
As with many malignancies, the carcinogenesis of  HCC is a 
multi-step process involving a number of  different genetic 
alterations that ultimately lead to malignant transformation 
of  the hepatocyte. It is postulated that HBV infection 
causes HCC via direct and indirect pathways. Continuous 
hepatocyte injury and regeneration in cirrhosis of  the liver 
leads to increased liver cell turnover and hence accumulation 
of  critical mutations in the host genome. This may result in 
genetic alterations, such as chromosomal rearrangements 
as well as activation of  cellular oncogenes or inactivation 
of  tumour suppressor genes. However a higher rate of  
chromosomal abnormalities is found in HBV-related 
HCC than those linked to other risk factors[7,8]. Alternative 
mechanisms in HBV carcinogenesis must also be involved. 
HBV belongs to the group of  oncogenic viruses known 
as hepadna virus. It is able to integrate its DNA into the 
genome of  the infected cell. Integrated HBV sequences 
have been observed in established hepatoma cell lines and in 
about 80% of  human HBV related HCCs[9]. It is postulated 
that the HBV DNA integration may confer a selective 
growth advantage on target cells and leads to the onset 
of  tumor progression. The integration sites are frequently 
detected in cellular genes involving cell signaling or growth 
control. Host chromosomal instability is also enhanced 
by HBV DNA integration. Large inverted duplications, 
deletions, amplification, chromosomal translocation have 
all been observed to be associated with HBV integration. 
In addition, the regulatory proteins HBx and the PreS2 
activators can exert a tumor promoter-like function, 
resulting in positive selection of  cells producing a functional 
regulatory protein.
HCV CARCINOGENESIS
HCV infection is a more important factor than HBV in 
the development of  HCC in western countries. Markers of  
HCV infection are found in a higher proportion of  HCC 
patients than that in most of  the Asian countries; ranging 
from 44% to 66% in Italy, 27% to 58% in France, 60% 
to 75% in Spain[10]. Japan, unlike other Asian countries, 
also has a high proportion of  HCC caused by HCV 
infection accounting for 80% to 90% of  all the cases[10]. 
www.wjgnet.com
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HCC risk increases to 17-fold in HCV-infected patients 
compared with HCV-negative subjects[11]. The risk of  
HCC occurrence is different among all HCV patients. It is 
a function of  the degree of  liver fibrosis and the time of  
acquisition of  the infection. The risk for cirrhotic HCV 
patients (F4) was the highest with 5.8% per year, compared 
to those who had less fibrosis (F1-3, 0.5% to 2.6%)[12]. 
Because of  the absence of  reverse transcription activity 
of  the HCV RNA virus, its viral genome unlike HBV is 
not able to integrate into the genome of  the infected cell. 
Therefore, HCV causes HCC via an indirect pathway by 
causing chronic inflammation, cell death, proliferation 
and cirrhosis. Accordingly, HCV-related HCCs are almost 
exclusively found in patients with cirrhosis. However, 
there are studies raising the possibility that HCV may also 
operate through other pathways in promoting malignant 
transformation of  hepatocytes. HCCs without cirrhosis in 
HCV-infected patients, though rare, have been reported. 
The transforming potential of  NS3 protein and core 
protein has been described. 
CLINICAL DIFFERENCES BETWEEN HBV- 
AND HCV-RELATED HCC
Apart from the difference in the carcinogenic mechanisms, 
there are a number of  clinical differences between HBV- 
and HCV-related HCC. For reasons yet to be known there 
is a larger proportion of  male HBV infected patients 
with HCC than the HCV counterpart. The male-to-
female ratio is higher in HBV-related HCC than in HCV-
related HCC (6.7:1 and 3.3:1 respectively in one study)[13]. 
Studies consistently show that HCC develops 10 years 
earlier in HBV carriers than in HCV carriers, a difference 
possibly due to the earlier age at exposure to the causative 
agent[13,14]. 
Due to the d i f ferent mechanisms involved in 
carcinogenesis, their rate of  HCC development is also 
different. In a Japanese study, 795 patients with viral or 
alcoholic cirrhosis were observed from 1974 to 1989. Two 
hundred and twenty five patients (27.8%) developed HCC. 
The cumulative rates of  HCC development in the 180 HBV 
cirrhotic subgroup at 3, 5, 10 and 15 years after follow 
up were 7.2%, 14.2%, 27.2% and 27.2% respectively. At 
9 years after the follow up, the rate of  HCC development 
began to decrease, and the cumulative rate remained the 
same thereafter. The corresponding rates in HCV-related 
cirrhosis were 10.4%, 21.5%, 53.2% and 75.2% respectively 
in the 349 HCV patients. The authors conclude that the 
cumulative rate of  HCC occurrence has a linear relationship 
with time in HCV patients whereas it seems to plateau 
after 10 years for HBV patients[15,16]. However, according 
to an Italian study, the cumulative rates of  HCC at 5, 10 
and 15 years continue to increase with 6.5%, 23.4% and 
31.9% for patients with HBV-related cirrhosis, and 4.6%, 
24% and 56.2% for patients with HCV-related cirrhosis, 
respectively[17]. At the time of  HCC diagnosis, a higher 
proportion of  HCV infected patients than HBV infected 
patients has advanced liver histology and has a higher Child 
Pugh’s score[13].  
The HCC tumor size and the growth pattern also tend 
to be different between HBV- and HCV-related HCCs. In 
most patients with HCV-related HCC, the tumors are more 
likely to be solitary, smaller sized and encapsulated whereas 
HBV-related HCC are more commonly infiltrative and 
multinodular[18]. Extensive hepatic involvement and portal 
vein invasion by the tumor were found in 44% and 52% 
respectively in 95 HBsAg-positive HCC patients compared 
to 25% and 28% respectively in 370 HBsAg-seronegative 
HCC patients[19].
NATURAL HISTORY OF HCC
The natural history of  HCC depends on tumour growth 
characteristics as well as the underlying liver cirrhosis. The 
majority of  hepatitis-related HCC develops in cirrhotic 
livers with a relatively poor liver reserve. Given a wide 
range of  tumor doubling time, some patients may die 
from liver failure before the tumor grows to an advanced 
stage. Features of  HCC shown to indicate more aggressive 
behaviour include poorly differentiated histology, lack of  
fibrous capsule, large tumour size, early vascular invasion 
and elevated serum levels of  alpha fetoprotein (AFP). 
Tumor growth rates have a wide range of  variability even 
among patients of  the same region and regardless of  
disease stage. Doubling time ranges from 1 mo to 19 mo 
with a median of  4 to 6 mo[20]. 
Vascular supply of  HCC is derived from the hepatic 
arterial network and the efferent vessels of  portal 
origin have been described to create arterioportal or 
arteriovenous shunts which serve as a low resistance path 
for tumour thrombi fragments to survive and spread 
within the portal efferent network. In a large autopsy study 
from Sweden, 56% of  HCC had evidence of  vascular 
invasion but biliary tract involvement was observed in 
only 4%[25]. In another autopsy study in Japan, vascular 
involvement was noted up to 82% and the likelihood of  
vascular involvement was related not only to tumor size 
but also the macroscopic types[26]. The frequency of  portal 
vein invasion is higher than hepatic vein invasion[27]. 
A retrospective analysis was performed in the United 
States of  America on 347 HCC patients who received a 
metastatic workup including bone scans and computed 
tomography scans of  the chest, abdomen, and pelvis. 
Clinical and tumor characteristics were evaluated as risk 
factors for metastasis by univariate and multivariate methods. 
One hundred forty-five patients had metastases: 72 had 
thoracic, 57 had abdominal, and 34 had bone metastases. 
Poor tumour differentiation, multilobular spread, and 
tumour size of  5 cm or more were the strongest predictors 
of  metastatic disease by logistic regression analysis[28]. 
In a Japanese study, the relationship between HCC specimen 
staining for AFP, serum AFP levels and pathological 
findings were examined. The disease prognosis was studied 
with respect to the staining for AFP in excised tumors. 
The mean serum AFP level in patients with positive AFP 
staining was significantly higher than in those with negative 
AFP staining. No significant relationship was found between 
AFP positivity and tumor size, tumor encapsulation, degree 
of  vascular invasion, or the histological differentiation 
grade of  the tumor. However, patients with AFP-positive 
1654        ISSN 1007-9327       CN 14-1219/R     World J Gastroenterol       March 21, 2008      Volume 14        Number 11
www.wjgnet.com
carcinomas had a poorer prognosis than those with AFP-
negative carcinomas (5-year survival rate of  AFP-positive 
and negative groups were 26.7% and 56.5%, respectively)[29].
PREDICTION OF SURVIVAL
The prognosis of  HCC has been dismal because patients 
with HCC usually present late and have already developed 
advanced liver cirrhosis. Curative resection was seldomly 
possible. Therefore, the life expectancies of  patients with 
newly diagnosed HCC were classically measured in terms 
of  weeks to months with mortality to incidence ratio close 
to 1. Due to the increased awareness of  the disease and 
HCC surveillance programmes in some parts of  the world, 
HCC can be diagnosed at its earlier phase permitting 
timely curative interventions. In a Hong Kong study[30], the 
clinical features and disease outcome of  306 HCC patients 
were analysed. The characteristics of  those present with 
symptoms and those with the disease diagnosed by 
screening were compared. One hundred and forty two 
patients with HCC diagnosed by regular screening have a 
significantly lower serum AFP level, smaller tumour size, 
less bilobar disease, less portal vein infiltration and less 
distant metastasis compared with the 164 symptomatic 
subjects. As a result a higher proportion of  patients could 
undergo curative resection (26.8% vs 7.9%). 
Scores and models for predicting survival probability 
are invaluable to tailor suitable treatment options. The 
traditional TNM cancer staging system has limited 
applicability as it does not take into account the possible 
poor liver function in HCC patients. Eighty percent of  
HCC patients cannot be treated with surgery, so the 
tumour pathologic information needed in TMN cancer 
staging is not available. This further limits its prognostic 
use. Child-Pugh score on the other hand was designed to 
predict survival in liver cirrhosis without any component 
of  HCC tumour morphology and consideration of  disease 
extension. The first widely accepted staging system to 
predict survival for HCC which incorporates tumour 
biology and hepatic function was proposed by Okuda 
et al in 1985[31]. Tumour size, serum bilirubin, albumin and 
the presence of  ascites are included in the calculation of  
Okuda staging. In a Hong Kong study of  106 untreated 
unresectable HCC patients performed in 2001, the median 
survival was 5.1 mo in stageⅠ, 2.7 mo in stage Ⅱ and 
1.0 mo in stage Ⅲ. These figures were remarkably similar 
to the original report by Okuda, in which the median 
survival of  stagesⅠ, Ⅱ and Ⅲ disease was 8.3, 2, and 
0.7 mo respectively. Among other staging systems, only 
Okuda staging was independently correlated with prognosis 
in the final multivariate model. As more treatment options 
become available, newer prognostic models are introduced. 
The Cancer of  the Liver Italian Group Programme 
(CLIP) proposed a staging system which has been shown 
to be superior to that of  the Okuda stage with a higher 
number of  categories and greater discriminant ability. It 
reveals a subgroup of  patients with an impressively more 
favourable prognosis who could be candidates for more 
aggressive therapeutic strategies. On the other hand, it 
also sorts out a subset of  patients with a median survival 
long enough to be considered for clinical trials of  palliative 
antineoplastic treatment. It includes Child-Pugh score, 
tumour size, presence of  portal vein thrombosis, and 
serum AFP. Another survival model is the Barcelona Clinic 
Liver Group (BCLC) staging system which also effectively 
selects patients for aggressive treatments. It is constructed 
from several cohort studies and randomized controlled 
trials (RCTs) by the Barcelona group. This classification 
uses variables related to tumour stage, liver functional 
status, physical status, and cancer-related symptoms, and 
links the five stages described (0, A-D) with a treatment 
algorithm. The therapeutic approach configured into the 
BCLC staging system for patients with non-surgical HCC 
is based on the study by Llovet et al in which asymptomatic 
patients without evidence of  disease extension (vascular 
invasion or metastasis) had significantly better survival 
compared to those with more advanced disease[28]. Such 
patients are classified as having intermediate HCC and may 
be better candidates for tumour ablative interventions or 
chemoembolization. 
HBV VACCINATION
HBV vaccination has been shown to be effective to protect 
against HBV infection. The vaccination is recommended 
to high risk population groups such as health care workers, 
patients with immunocompromised states or with chronic 
liver diseases or with the need for regular blood product 
transfusion or hemodialysis, and neonates of  HBV carrier 
mothers. Vertical and early horizontal transmission is 
the major route of  HBV transmission in high prevalent 
areas. The transmission rate was estimated to be as high 
as 90% in HBeAg positive mothers. The use of  HBV 
vaccine and hepatitis B immunoglobulin (HBIG) can 
greatly reduce the infection rate of  the neonates to 10% 
to 15%[33]. The use of  vaccination in all newborns can 
reduce the chance of  infection acquired via other routes 
during early childhood and thus preventing the prolonged 
immunotolerant phase of  this unique infection. By 
eliminating HBV seroprevalence in the population, HCC 
incidence should be greatly reduced in high prevalence 
areas. In Taiwan, a universal HBV vaccination programme 
was carried out in 1984. A study had shown that the HCC 
incidence in children was decreased since the introduction 
of  the vaccination programme[34]. In that study, the author 
showed that the annual incidence of  childhood liver cancer 
was reduced from 0.70 per 100 000 to 0.36 per 100 000 in 
the children born between 1981 to 1986 and 1990 to 1994 
respectively. Therefore a similar decrease in the adult HCC 
incidence is expected in the future. Likewise, vaccination 
prog rammes in high endemic areas l ike Gambia , 
intermediate endemic areas like Italy had shown impressive 
reduction of  the HBV seroprevalence. This may transform 
to a reduction in HCC incidence similar to the Taiwan 
study. However, the development of  an effective vaccine 
has been hampered by the high genetic variability of  HCV. 
CONCLUSION
HCC is a complex neoplasm often occur ring in a 
preneoplastic cirrhotic liver, and thus, survival and treatment 
options depend on variables of  both HCC and cirrhosis. 
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Among chronic viral hepatitis-related HCC, differences 
in carcinogenesis and clinical presentation exist between 
HBV and HCV patients. Survival models using tumour size, 
invasiveness, liver function, patient physical performance 
status can predict prognosis and guide treatments.
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